eBulletin Newsletter

NCCN Flash Updates: NCCN Templates Updated for Castleman Disease and T-Cell Lymphoma

NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates®) for Castleman Disease to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Castleman Disease v1.2024.

 

  • The NCCN Guidelines® reference link has been updated on ALL the NCCN Templates® For Castleman Disease:
    • NCCN Guidelines for Castleman Disease v.1.2024
  • Tall Man Lettering has been updated for the following agents:
    • CycloPHOSphamide
    • DexAMETHasone
  • Changes to the notes in the Myeloid Growth Factor Therapy section have been made on the following templates:
    • CD8: CHOP (CycloPHOSphamide/DOXOrubicin/VinCRIStine/PredniSONE) + RiTUXimab
    • CD9: CHOP (CycloPHOSphamide/DOXOrubicin/VinCRIStine/PredniSONE)
    • CD10: CVAD (CycloPHOSphamide/VinCRIStine/DOXOrubicin/DexAMETHasone) + RiTUXimab
    • CD11: CVAD (CycloPHOSphamide/VinCRIStine/PredniSONE)
  • Drug information notes for the following agents have been updated in the Supportive Care, Monitoring and Hold Parameters, and/or Safety Parameters and Special Instructions sections:
    • Bortezomib
    • CycloPHOSphamide
    • PredniSONE
    • RiTUXimab

 

NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates®) for T-Cell Lymphoma and T-Cell Prolymphocytic Leukemia to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for T-Cell Lymphoma v1.2024.

  • The following New NCCN Templates® have been published:
    • TCL49: Brigatinib
    • TCL50: Lorlatinib
    • TCL51: Ceritinib
    • TCL52: Oral AzaCITIDine
    • TCL54: Bendamustine + Brentuximab Vedotin
    • TCL55: GELAD (Gemcitabine/Etoposide/Pegaspargase/DexAMETHasone)
    • TPLL5: Ruxolitinib

 

 

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients®, please visit NCCN.org/patientguidelines.

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.

About NCCN Flash Updates™

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content.

Subscribe to NCCN Flash Updates™

Third Party Content: The NCCN Content may contain content (such as figures, tables or illustrations) that NCCN licenses from third parties as displayed on NCCN Third Party Content site: https://private.filesanywhere.com/fs/v.aspx?v=8a6d65cfa19ea4bda0a3&C=6241. Licensee shall be solely responsible for obtaining permissions from each such third party to use any such Third Party Content in the Permitted Works. 

Access information on permissions and licensing of NCCN Content

Users may unsubscribe from Flash Updates at any time by contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.

3025 Chemical Road, Suite 100, Plymouth Meeting, PA 19462
Phone: 215-690-0300
Fax: 215-690-0280
Copyright © National Comprehensive Cancer Network, All Rights Reserved.

No portion of this Site or any NCCN Content may be copied, transferred, reproduced, modified, or otherwise used for any purpose without NCCN’s express written permission.
See Legal Notices Section for additional notices and terms governing your use of this Site.